Delivery Order SPE2DB24D2100-SPE2DB25FBFNL
- Not listed
- The Defense Logistics Agency awarded a $6,925.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 grams of Opzelura 1.5% cream, with a completion date of July 22, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves...
- The Defense Logistics Agency awarded a $1,513.53 delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of Opzelura 1.5% cream in 60-gram quantities. This firm fixed-price contract, which is not set-aside for any specific business category, is scheduled for completion by June 23, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,438.54 to AmerisourceBergen Drug Corp for Opzelura 1.5% Cream (60 grams) on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively to the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract executed under...
- The Defense Logistics Agency awarded a $8.3K delivery order to AmerisourceBergen Drug Corp for 60 grams of Opzelura 1.5% cream on August 4, 2025, with completion targeted for August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Opzelura 1.5% Cream in a 60-gram format, with a ceiling value of $2,046.89. This competitively awarded, firm fixed-price contract is classified as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The delivery order carries...
- The Defense Logistics Agency awarded a $7,140.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 grams of Opzelura 1.5% cream on April 21, 2025, with completion expected by April 22, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Opzelura 1.5% cream in 60-gram quantities, with a ceiling value of $6,776.02 and an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999...
- The Defense Logistics Agency awarded a $26,873.19 delivery order to AmerisourceBergen Drug Corp on May 15, 2025, for the supply of Opzelura 1.5% cream in 60-gram units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of May 16, 2025. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 21, 2025, for the supply of Opzelura 1.5% cream in 60-gram quantities, with a contract ceiling value of $1,310.45. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of April 22, 2025....
- The Defense Logistics Agency awarded a delivery order valued at $2,073.05 to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Opzelura 1.5% Cream in 60-gram units. This firm fixed-price delivery order, with an ultimate completion date of April 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical vendor that serves military...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFNLDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,460.52 for Opzelura 1.5% Cream (60 grams) with a completion date of July 31, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $1 billion through December 2026. The contract carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement across military and veteran healthcare systems. The delivery order for this dermatological treatment product exemplifies the company's extensive portfolio supporting DLA's Medical Supply Chain with a comprehensive range of pharmaceuticals, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This transaction reflects the company's established capability to fulfill federal medical supply requirements through open competition and demonstrates its role in supporting Defense Health Agency operations and broader government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 7/30/25 |